At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Oxycodone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain
In Brief
A Phase 4 clinical trial evaluating Oxycodone for Cancer and Pain. Completed, enrolled 30 participants across 4 sites.
Detailed Summary
This study is to evaluate the efficacy and safety of a titration method by selects 10 mg control-released (CR) oxycodone tablet as background drug in combined with immediate-released (IR) oxycodone, compared to conventional titration method with immediate-released (IR) oxycodone in patients with moderate to severe cancer pain in Taiwan.
Study Details
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartSep 2016
First PostedJun 2017
Primary CompletionDec 2018
TodayJul 2026
First PostedJun 5, 2017
Enrollment StartSep 1, 2016
Primary CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.1 years ago
Interventions
Oxycodonedrug
Every 12 hours for control-released oxycodone (OxyContin®)
Oxycodonedrug
Every 6 hours for immediate-released oxycodone (OxyNorm®)